SLC16A3

Across TCGA pan-cancer cohorts, SLC16A3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLC16A3 data layer compared with 28 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SLC16A3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC16A3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where SLC16A3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.300	0.510	<.001	101	view →
CCRCC	OS	Tertile	All	0.718	0.957	<.001	54	view →
GBM	DFS	Tertile	All	0.260	0.548	<.001	19	view →
UCEC	OS	Tertile	All	1.000	0.904	.027	16	view →
LUAD	DFS	Median	All	0.462	0.846	.012	6	view →
HNSC	DFS	Median	IV	0.328	0.889	.014	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SLC16A3–PDAC (DFS)

Open the PDAC breakdown →